{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:20:52Z","timestamp":1791379252458,"version":"4.3.2"},"reference-count":94,"publisher":"MedWorks Media","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacol Bull"],"abstract":"<jats:p>Antiepileptic drugs (AEDs) are used in various pathologies such as including epilepsy, migraine, neuropathic pain, etc. They can improve symptoms but cause adverse events (ADRs). Case reports have reported that one rare but serious AED-induced adverse reaction that has appeared in case reports is myotoxicity from rhabdomyolysis. Rhabdomyolysis can be induced by a therapeutically dosed occur with therapeutic doses of antiepileptic drugs and is in most cases reversible, although rarely it can cause serious complications. Clinical manifestations of rhabdomyolysis range from a single isolated asymptomatic rise in serum CK levels to severe electrolyte imbalances, cardiac arrhythmia, acute and disseminated renal failure, intravascular coagulation, and other symptoms. Many clinical cases reported that both conventional older and newer AEDs, as well as propofol, can cause rhabdomyolysis, even if there are no conclusive data. It has recently been shown that genetic factors certainly contribute to adverse reactions of antiepileptic drugs. A study of genetic polymorphism in patients with AED-induced rhabdomyolysis may be useful to explain the rarity of this adverse event and to improve the treatment of these AED patients, in terms of AED type and dose adjustment.<\/jats:p>","DOI":"10.64719\/pb.4421","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:39:16Z","timestamp":1761046756000},"page":"105-116","source":"Crossref","is-referenced-by-count":4,"title":["Myotoxicity Induced by Antiepileptic Drugs: Could be a Rare but Serious Adverse Event?"],"prefix":"10.64719","volume":"51","author":[{"given":"Antonio","family":"Siniscalchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Mintzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovambattista De","family":"Sarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Gallelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54175","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"key":"ref1","unstructured":"Palleria C, Di Paolo A, Giofre C, Caglioti C, Leuzzi G, Siniscalchi A et al. Pharmacokinetic drug-drug interaction and their implication in clinical management. Journal of Research in Medical Sciences: The Official Journal of Isfahan University of Medical Sciences. 2013;18(7):601\u2013610. Epub 2014\/02\/12."},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Gallelli L, Siniscalchi A, Palleria C, Mumoli L, Staltari O, Squillace A et al. Adverse Drug Reactions Related to Drug Administration in Hospitalized Patients. Current Drug Safety. 2017;12(3):171\u2013177. Epub 2017\/06\/20.","DOI":"10.2174\/1574886312666170616090640"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Gallelli L, Gratteri S, Siniscalchi A, Cione E, Sirico S, Seminara P et al. Drug-Drug Interactions in Cocaine-users and their Clinical Implications. Current Drug Abuse Reviews. 2017;10(1):25\u201330. Epub 2017\/12\/01.","DOI":"10.2174\/1874473710666170920143344"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Gareri P, De Fazio P, Gallelli L, De Fazio S, Davoli A, Seminara G et al. Venlafaxine-propafenone interaction resulting in hallucinations and psychomotor agitation. The Annals of Pharmacotherapy. 2008;42(3):434\u2013438. Epub 2008\/02\/28.","DOI":"10.1345\/aph.1K405"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Sieb JP, Gillessen T. Iatrogenic and toxic myopathies. Muscle & Nerve. 2003;27(2):142\u2013156. Epub 2003\/01\/28.","DOI":"10.1002\/mus.10244"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Janssen L, Frambach S, Allard NAE, Hopman MTE, Schirris TJJ, Voermans NC et al. Skeletal muscle toxicity associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. Leukemia. 2019;33(8):2116\u20132120. Epub 2019\/03\/16.","DOI":"10.1038\/s41375-019-0443-7"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Janssen L, Allard NAE, Saris CGJ, Keijer J, Hopman MTE, Timmers S. Muscle Toxicity of Drugs: When Drugs Turn Physiology into Pathophysiology. Physiological Reviews. 2020;100(2):633\u2013672. Epub 2019\/11\/22.","DOI":"10.1152\/physrev.00002.2019"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Pascuzzi RM. Drugs and toxins associated with myopathies. Current Opinion in Rheumatology. 1998;10(6):511\u2013520. Epub 1998\/11\/13.","DOI":"10.1097\/00002281-199811000-00003"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Iaccarino L, Bartoloni E, Gerli R, Alunno A, Barsotti S, Cafaro G et al. Drugs in induction and treatment of idiopathic inflammatory myopathies. Auto-Immunity Highlights. 2014;5(3):95\u2013100. Epub 2015\/05\/23.","DOI":"10.1007\/s13317-014-0065-z"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Melli G, Chaudhry V, Cornblath DR. Rhabdomyolysis: an evaluation of 475 hospitalized patients. Medicine. 2005;84(6):377\u2013385. Epub 2005\/11\/04.","DOI":"10.1097\/01.md.0000188565.48918.41"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Jiang W, Wang X, Zhou S. Rhabdomyolysis induced by antiepileptic drugs: characteristics, treatment and prognosis. Expert Opinion on Drug Safety. 2016;15(3):357\u2013365. Epub 2016\/01\/12.","DOI":"10.1517\/14740338.2016.1139572"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Dalakas MC. Toxic and drug-induced myopathies. Journal of Neurology, Neurosurgery, and Psychiatry. 2009;80(8):832\u2013838. Epub 2009\/07\/18.","DOI":"10.1136\/jnnp.2008.168294"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Guis S, Mattei JP, Liote F. Drug-induced and toxic myopathies. Best Practice & Research Clinical Rheumatology. 2003;17(6):877\u2013907. Epub 2004\/05\/05.","DOI":"10.1016\/j.berh.2003.11.002"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Chatzizisis YS, Misirli G, Hatzitolios AI, Giannoglou GD. The syndrome of rhabdomyolysis: complications and treatment. European Journal of Internal Medicine. 2008;19(8):568\u2013574. Epub 2008\/12\/03.","DOI":"10.1016\/j.ejim.2007.06.037"},{"key":"ref15","unstructured":"Torres PA, Helmstetter JA, Kaye AM, Kaye AD. Rhabdomyolysis: pathogenesis, diagnosis, and treatment. The OchsnerJournal. 2015;15(1):58\u201369. Epub 2015\/04\/02."},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Cabral BMI, Edding SN, Portocarrero JP, Lerma EV. Rhabdomyolysis. Disease-a-month: DM. 2020;66(8):101015. Epub 2020\/06\/14.","DOI":"10.1016\/j.disamonth.2020.101015"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Huerta-Alardin AL, Varon J, Marik PE. Bench-to-bedside review: Rhabdomyolysis\u2014an overview for clinicians. Crit Care. 2005;9(2):158\u2013169. Epub 2005\/03\/19.","DOI":"10.1186\/cc2978"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Chavez LO, Leon M, Einav S, Varon J. Beyond muscle destruction: a systematic review of rhabdomyolysis for clinical practice. Crit Care. 2016;20(1):135. Epub 2016\/06\/16.","DOI":"10.1186\/s13054-016-1314-5"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Cervellin G, Comelli I, Benatti M, Sanchis-Gomar F, Bassi A, Lippi G. Non-traumatic rhabdomyolysis: Background, laboratory features, and acute clinical management. Clinical Biochemistry. 2017;50(12):656\u2013662. Epub 2017\/02\/27.","DOI":"10.1016\/j.clinbiochem.2017.02.016"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Cervellin G, Comelli I, Lippi G. Rhabdomyolysis: historical background, clinical, diagnostic and therapeutic features. Clinical Chemistry and Laboratory Medicine. 2010;48(6):749\u2013756. Epub 2010\/03\/20.","DOI":"10.1515\/CCLM.2010.151"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Shapiro ML, Baldea A, Luchette FA. Rhabdomyolysis in the intensive care unit. Journal of Intensive Care Medicine. 2012;27(6):335\u2013342. Epub 2011\/03\/26.","DOI":"10.1177\/0885066611402150"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Bosch X, Poch E, Grau JM. Rhabdomyolysis and acute kidney injury. The New England Journal of Medicine. 2009;361(1):62\u201372. Epub 2009\/07\/03.","DOI":"10.1056\/NEJMra0801327"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Lane R, Phillips M. Rhabdomyolysis. BMJ. 2003;327(7407):115\u2013116. Epub 2003\/07\/19.","DOI":"10.1136\/bmj.327.7407.115"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Chamberlain MC. Rhabdomyolysis in children: a 3-year retrospective study. Pediatric Neurology. 1991;7(3):226\u20138. Epub 1991\/05\/01.","DOI":"10.1016\/0887-8994(91)90091-X"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Watanabe T. Rhabdomyolysis and acute renal failure in children. Pediatr Nephrol. 2001;16(12):1072\u20131075. Epub 2002\/01\/17.","DOI":"10.1007\/s004670100030"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Star K, Iessa N, Almandil NB, Wilton L, Curran S, Edwards IR et al. Rhabdomyolysis reported for children and adolescents treated with antipsychotic medicines: a case series analysis. Journal of Child and Adolescent Psychopharmacology. 2012;22(6):440\u2013451. Epub 2012\/12\/14.","DOI":"10.1089\/cap.2011.0134"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Park JI, Park TW. Rhabdomyolysis and Neuroleptic Malignant Syndrome Associated with Very Low-dose Antipsychotics in Children and Adolescent. Clinical Psychopharmacology and Neuroscience: The Official Scientific Journal of the Korean College of Neuropsychopharmacology. 2019;17(3):450\u2013452. Epub 2019\/07\/30.","DOI":"10.9758\/cpn.2019.17.3.450"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"van\u2018t Kruys K, Zonneveld R, Liesdek S, Zijlmans W. Rhabdomyolysis in Children: Three Exotic Presentations from Suriname. Journal of Tropical Pediatrics. 2019;65(2):199\u2013202. Epub 2018\/08\/08.","DOI":"10.1093\/tropej\/fmy043"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Ju Y, Qiao H, Zhang Y, Li Y. Three Cases of Rhabdomyolysis Induced by Viral Infections in Children and Literature Review. Chinese medical sciences journal = Chung-kuo i hsueh k\u2019o hsueh tsa chih. 2020;35(4):383\u2013386. Epub 2021\/01\/09.","DOI":"10.24920\/003663"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Tournadre A. Statins myalgia, and rhabdomyolysis. Joint Bone Spine. 2020;87(1):37\u201342. Epub 2019\/02\/09.","DOI":"10.1016\/j.jbspin.2019.01.018"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Danielak D, Karazniewicz-Lada M, Glowka F. Assessment of the Risk of Rhabdomyolysis and Myopathy During Concomitant Treatment with Ticagrelor and Statins. Drugs. 2018;78(11):1105\u20131112. Epub 2018\/07\/14.","DOI":"10.1007\/s40265-018-0947-x"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Coste J, Billionnet C, Rudnichi A, Pouchot J, Dray-Spira R, Giral P et al. Statins for primary prevention and rhabdomyolysis: A nationwide cohort study in France. European Journal of Preventive Cardiology. 2019;26(5):512\u2013521. Epub 2018\/05\/26.","DOI":"10.1177\/2047487318776831"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Botillo-Martin C, Gonzalez-Pablos E. Rhabdomyolysis of Multifactorial Origin in Schizophrenia: Antipsychotics, Statins, Trauma. Journal of Clinical Psychopharmacology. 2018;38(3):261\u2013263. Epub 2018\/04\/04.","DOI":"10.1097\/JCP.0000000000000880"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Gallelli L, Ferraro M, Spagnuolo V, Rende P, Mauro GF, De Sarro G. Rosuvastatin-induced rhabdomyolysis probably via CYP2C9 saturation. Drug Metabolism and Drug Interactions. 2009;24(1):83\u201387. Epub 2009\/04\/10.","DOI":"10.1515\/DMDI.2009.24.1.83"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Siniscalchi A, Gallelli L, De Sarro G, Malferrari G, Santangelo E. Antiepileptic drugs for central post-stroke pain management. Pharmacological Research. 2012;65(2):171\u2013175. Epub 2011\/09\/20.","DOI":"10.1016\/j.phrs.2011.09.003"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Siniscalchi A, Gallelli L, Russo E, De Sarro G. A review on antiepileptic drugs-dependent fatigue: pathophysiological mechanisms and incidence. European Journal of Pharmacology. 2013;718(1)(3):10\u201316. Epub 2013\/09\/21.","DOI":"10.1016\/j.ejphar.2013.09.013"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Engel JN, Mellul VG, Goodman DB. Phenytoin hypersensitivity: a case of severe acute rhabdomyolysis. The American Journal of Medicine. 1986;81(5):928\u2013930. Epub 1986\/11\/01.","DOI":"10.1016\/0002-9343(86)90371-2"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Santos-Calle FJ, Borras-Blasco J, Navarro-Ruiz A, Plaza Macias I. Unsuspected rhabdomyolysis associated with phenytoin. International Journal of Clinical Pharmacology and Therapeutics. 2005;43(9):436\u2013440. Epub 2005\/09\/17.","DOI":"10.5414\/CPP43436"},{"key":"ref39","unstructured":"Korman LB, Olson MJ. Phenytoin-induced hepatitis, rhabdomyolysis, and renal dysfunction. Clinical Pharmacy. 1989;8(7):514\u2013515. Epub 1989\/07\/01."},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"di Russo P, Perrini P, Benedetto N, Siciliano G. Phenytoin-induced rhabdomyolysis: Timely recognition for safely remission. Neurology India. 2016;64(4):793\u2013794. Epub 2016\/07\/07.","DOI":"10.4103\/0028-3886.185415"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Zwaenepoel B, Le Roy S, Decruyenaere A, Parys S, Schurgers M, Stevens O. Letter to the editor: phenytoin-induced rhabdomyolysis. Acta Neurologica Belgica. 2019;119(2):293\u2013294. Epub 2018\/11\/06.","DOI":"10.1007\/s13760-018-1032-7"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Kim H, Jo S, Park KW, Han SH, Lee SA. A Case of Phenytoin-induced Rhabdomyolysis in Status Epilepticus. Journal of Epilepsy Research. 2016;6(1):36\u201338. Epub 2016\/07\/09.","DOI":"10.14581\/jer.16007"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Pinkston R, Walker LA. Multiorgan system failure caused by valproic acid toxicity. The American Journal of Emergency Medicine. 1997;15(5):504\u2013506. Epub 1997\/09\/01.","DOI":"10.1016\/S0735-6757(97)90195-9"},{"key":"ref44","unstructured":"Walker CP, Deb S. Rhabdomyolysis and Hepatotoxicity From Valproic Acid: Case Reports. Journal of Pharmacy Practice. 2019:897190019882880. Epub 2019\/10\/30."},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Roodhooft AM, Van Dam K, Haentjens D, Verpooten GA, Van Acker KJ. Acute sodium valproate intoxication: occurrence of renal failure and treatment with haemoperfusion-haemodialysis. European Journal of Pediatrics. 1990;149(5):363\u2013364. Epub 1990\/02\/01.","DOI":"10.1007\/BF02171569"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Chattergoon DS, McGuigan MA, Koren G, Hwang P, Ito S. Multiorgan dysfunction and disseminated intravascular coagulation in children receiving lamotrigine and valproic acid. Neurology. 1997;49(5):1442\u20131444. Epub 1997\/12\/31.","DOI":"10.1212\/WNL.49.5.1442"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Meyer S, Martin T, Loffler G, Gortner L. Severe rhabdomyolysis caused by valproic Acid in a neonate with seizures and chromosomal abnormalities. Klinische Padiatrie. 2011;223(7):434\u2013435. Epub 2011\/05\/27.","DOI":"10.1055\/s-0031-1277216"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Kottlors M, Jaksch M, Ketelsen UP, Weiner S, Glocker FX, Lucking CH. Valproic acid triggers acute rhabdomyolysis in a patient with carnitine palmitoyltransferase type II deficiency. Neuromuscular Disorders: NMD. 2001;11(8):757\u2013759. Epub 2001\/10\/12.","DOI":"10.1016\/S0960-8966(01)00228-0"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Akiyama H, Haga Y, Sasaki N, Yanagisawa T, Hasegawa Y. A case of rhabdomyolysis in which levetiracetam was suspected as the cause. Epilepsy & Behavior Case Reports. 2014;2:152\u2013155. Epub 2015\/02\/11.","DOI":"10.1016\/j.ebcr.2014.08.001"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"Isaacson JE, Choe DJ, Doherty MJ. Creatine phosphokinase elevation exacerbated by levetiracetam therapy. Epilepsy & Behavior Case Reports. 2014;2:189\u2013191. Epub 2015\/02\/11.","DOI":"10.1016\/j.ebcr.2014.09.008"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Incecik F, Herguner OM, Besen S, Altunbasak S. Acute rhabdomyolysis associated with levetiracetam therapy in a child. Acta neurologica Belgica. 2016;116(3):369\u2013370. Epub 2015\/09\/25.","DOI":"10.1007\/s13760-015-0542-9"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Thomas L, Mirza MMF, Shaikh NA, Ahmed N. Rhabdomyolysis: a rare adverse effect of levetiracetam. BMJ Case Reports. 2019;12(8) Epub 2019\/08\/28.","DOI":"10.1136\/bcr-2019-230851"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Moinuddin IA. Suspected Levetiracetam-Induced Rhabdomyolysis: A Case Report and Literature Review. The American Journal of Case Reports. 2020;21:e926064. Epub 2020\/10\/29.","DOI":"10.12659\/AJCR.926064"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"Tuccori M, Lombardo G, Lapi F, Vannacci A, Blandizzi C, Del Tacca M. Gabapentin-induced severe myopathy. The Annals of Pharmacotherapy. 2007;41(7):1301\u20131305. Epub 2007\/06\/15.","DOI":"10.1345\/aph.1K077"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"Bilgir O, Calan M, Bilgir F, Kebapcilar L, Yuksel A, Yildiz Y et al. Gabapentin-induced rhabdomyolysis in a patient with diabetic neuropathy. Intern Med. 2009;48(12):1085\u20131087. Epub 2009\/06\/16.","DOI":"10.2169\/internalmedicine.48.1766"},{"key":"#cr-split#-ref56.1","unstructured":"Falconi D, Tattoli F, Brunetti C, De Prisco O, Gherzi M, Marazzi F et al. [Rhabdomyolysis from gabapentin: a case report]. Giornale italiano di nefrologia: organo ufficiale della Societa italiana di nefrologia. 2015;32"},{"key":"#cr-split#-ref56.2","unstructured":"(2) Epub 2015\/05\/26. Rabdomiolisi da gabapentin: a case report."},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"Coupal TM, Chang DR, Pennycooke K, Ouellette HA, Munk PL. Radiologic Findings in Gabapentin-Induced Myositis. Journal of Radiology Case Reports. 2017;11(4):30\u201337. Epub 2017\/06\/02.","DOI":"10.3941\/jrcr.v11i4.3092"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"Choi MS, Jeon H, Kim HS, Jang BH, Lee YH, Park HS et al. A case of gabapentin-induced rhabdomyolysis requiring renal replacement therapy. Hemodialysis International International Symposium on Home Hemodialysis. 2017;21(1):E4\u2013E8. Epub 2016\/07\/09.","DOI":"10.1111\/hdi.12458"},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"Qiu X, Tackett E, Khitan Z. A case of gabapentin overdose induced rhabdomyolysis requiring renal replacement therapy. Clinical Case Reports. 2019;7(8):1596\u20131599. Epub 2019\/08\/21.","DOI":"10.1002\/ccr3.2302"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"Schaub JE, Williamson PJ, Barnes EW, Trewby PN. Multisystem adverse reaction to lamotrigine. Lancet. 1994;344(8920):481. Epub 1994\/08\/13.","DOI":"10.1016\/S0140-6736(94)91818-X"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"Schwartz MD, Geller RJ. Seizures and altered mental status after lamotrigine overdose. Therapeutic Drug Monitoring. 2007;29(6):843\u2013844. Epub 2007\/11\/29.","DOI":"10.1097\/FTD.0b013e31815bf239"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"Karaoulanis SE, Syngelakis M, Fokas K. Rhabdomyolysis after lamotrigine overdose: a case report and review of the literature. Annals of General Psychiatry. 2016;15(6) Epub 2016\/02\/26.","DOI":"10.1186\/s12991-016-0093-3"},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"Ferguson LP, Dargan PI, Hood JL, Tibby SM. Life-threatening organ failure after lamotrigine therapy. Pediatric Neurology. 2009;40(5):392\u2013394. Epub 2009\/04\/22.","DOI":"10.1016\/j.pediatrneurol.2008.11.018"},{"key":"ref64","doi-asserted-by":"crossref","unstructured":"Cornfield DN, Tegtmeyer K, Nelson MD, Milla CE, Sweeney M. Continuous propofol infusion in 142 critically ill children. Pediatrics. 2002;110(6):1177\u20131181. Epub 2002\/11\/29.","DOI":"10.1542\/peds.110.6.1177"},{"key":"ref65","doi-asserted-by":"crossref","unstructured":"Parke TJ, Stevens JE, Rice AS, Greenaway CL, Bray RJ, Smith PJ et al. Metabolic acidosis and fatal myocardial failure after propofol infusion in children: five case reports. BMJ. 1992;305(6854):613\u2013616. Epub 1992\/09\/12.","DOI":"10.1136\/bmj.305.6854.613"},{"key":"ref66","doi-asserted-by":"crossref","unstructured":"Zaccheo MM, Bucher DH. Propofol infusion syndrome: a rare complication with potentially fatal results. Critical Care Nurse. 2008;28(3):18\u201326. quiz 7. Epub 2008\/06\/03.","DOI":"10.4037\/ccn2008.28.3.18"},{"key":"ref67","doi-asserted-by":"crossref","unstructured":"Zarovnaya EL, Jobst BC, Harris BT. Propofol-associated fatal myocardial failure and rhabdomyolysis in an adult with status epilepticus. Epilepsia. 2007;48(5):1002\u20131006. Epub 2007\/03\/27.","DOI":"10.1111\/j.1528-1167.2007.01042.x"},{"key":"ref68","doi-asserted-by":"crossref","unstructured":"Hanna JP, Ramundo ML. Rhabdomyolysis and hypoxia associated with prolonged propofol infusion in children. Neurology. 1998;50(1):301\u2013303. Epub 1998\/01\/27.","DOI":"10.1212\/WNL.50.1.301"},{"key":"ref69","doi-asserted-by":"crossref","unstructured":"Levin PD, Levin V, Weissman C, Sprung CL, Rund D. Therapeutic plasma exchange as treatment for propofol infusion syndrome. Journal of Clinical Apheresis. 2015;30(5):311\u2013313. Epub 2015\/01\/27.","DOI":"10.1002\/jca.21376"},{"key":"ref70","doi-asserted-by":"crossref","unstructured":"Vossler DG, Bainbridge JL, Boggs JG, Novotny EJ, Loddenkemper T, Faught E et al. Treatment of Refractory Convulsive Status Epilepticus: A Comprehensive Review by the American Epilepsy Society Treatments Committee. Epilepsy Currents. 2020;20(5):245\u2013264. Epub 2020\/08\/22.","DOI":"10.1177\/1535759720928269"},{"key":"ref71","doi-asserted-by":"crossref","unstructured":"Chawla J. Stepwise approach to myopathy in systemic disease. Frontiers in Neurology. 2011;2:49. Epub 2011\/09\/03.","DOI":"10.3389\/fneur.2011.00049"},{"key":"ref72","doi-asserted-by":"crossref","unstructured":"Gurwitz JH, Avorn J. The ambiguous relation between aging and adverse drug reactions. Annals of Internal Medicine. 1991;114(11):956\u2013966. Epub 1991\/06\/01.","DOI":"10.7326\/0003-4819-114-11-956"},{"key":"ref73","doi-asserted-by":"crossref","unstructured":"Borchelt M, Horgas AL. Screening an elderly population for verifiable adverse drug reactions. Methodological approach and initial data of the Berlin Aging Study (BASE) Annals of the New York Academy of Sciences. 1994;717:270\u2013281. Epub 1994\/06\/30.","DOI":"10.1111\/j.1749-6632.1994.tb12096.x"},{"key":"ref74","doi-asserted-by":"crossref","unstructured":"Scalco RS, Snoeck M, Quinlivan R, Treves S, Laforet P, Jungbluth H et al. Exertional rhabdomyolysis: physiological response or manifestation of an underlying myopathy. BMJ Open Sport & Exercise Medicine. 2016;2(1):e000151. Epub 2016\/12\/03.","DOI":"10.1136\/bmjsem-2016-000151"},{"key":"ref75","doi-asserted-by":"crossref","unstructured":"Scalco RS, Gardiner AR, Pitceathly RD, Zanoteli E, Becker J, Holton JL et al. Rhabdomyolysis: a genetic perspective. Orphanet Journal of Rare Diseases. 2015;10:51. Epub 2015\/05\/02.","DOI":"10.1186\/s13023-015-0264-3"},{"key":"ref76","doi-asserted-by":"crossref","unstructured":"Dlamini N, Voermans NC, Lillis S, Stewart K, Kamsteeg EJ, Drost G et al. Mutations in RYR1 are a common cause of exertional myalgia and rhabdomyolysis. Neuromuscular Disorders: NMD. 2013;23(7):540\u2013548. Epub 2013\/05\/01.","DOI":"10.1016\/j.nmd.2013.03.008"},{"key":"ref77","doi-asserted-by":"crossref","unstructured":"Knuiman GJ, Kusters B, Eshuis L, Snoeck M, Lammens M, Heytens L et al. The histopathological spectrum of malignant hyperthermia and rhabdomyolysis due to RYR1 mutations. Journal of Neurology. 2019;266(4):876\u2013887. Epub 2019\/02\/23.","DOI":"10.1007\/s00415-019-09209-z"},{"key":"ref78","doi-asserted-by":"crossref","unstructured":"Witting N, Laforet P, Voermans NC, Roux-Buisson N, Bompaire F, Rendu J et al. Phenotype and genotype of muscle ryanodine receptor rhabdomyolysis-myalgia syndrome. Acta Neurologica Scandinavica. 2018;137(5):452\u2013461. Epub 2018\/04\/11.","DOI":"10.1111\/ane.12885"},{"key":"ref79","doi-asserted-by":"crossref","unstructured":"Voermans NC, Snoeck M, Jungbluth H. RYR1-related rhabdomyolysis: A common but probably underdiagnosed manifestation of skeletal muscle ryanodine receptor dysfunction. Revue Neurologique. 2016;172(10):546\u2013558. Epub 2016\/09\/25.","DOI":"10.1016\/j.neurol.2016.07.018"},{"key":"ref80","doi-asserted-by":"crossref","unstructured":"Molenaar JP, Voermans NC, van Hoeve BJ, Kamsteeg EJ, Kluijtmans LA, Kusters B et al. Fever-induced recurrent rhabdomyolysis due to a novel mutation in the ryanodine receptor type 1 gene. Internal Medicine Journal. 2014;44(8):819\u2013820. Epub 2014\/08\/02.","DOI":"10.1111\/imj.12498"},{"key":"ref81","doi-asserted-by":"crossref","unstructured":"Brady S, Godfrey R, Scalco RS, Quinlivan RM. Emotionally-intense situations can result in rhabdomyolysis in McArdle disease. BMJ Case Reports. 2014;2014 Epub 2014\/10\/09.","DOI":"10.1136\/bcr-2013-203272"},{"key":"ref82","doi-asserted-by":"crossref","unstructured":"Liu M, Fan F, Zhang Y, Li J. The association of GATM polymorphism with statin-induced myopathy: a systematic review and meta-analysis. European Journal of Clinical Pharmacology. 2021;77(3):349\u2013357. Epub 2020\/10\/15.","DOI":"10.1007\/s00228-020-03019-3"},{"key":"ref83","doi-asserted-by":"crossref","unstructured":"Loscher W, Klotz U, Zimprich F, Schmidt D. The clinical impact of pharmacogenetics on the treatment of epilepsy. Epilepsia. 2009;50(1):1\u201323. Epub 2008\/07\/17.","DOI":"10.1111\/j.1528-1167.2008.01716.x"},{"key":"ref84","doi-asserted-by":"crossref","unstructured":"Balestrini S, Sisodiya SM. Pharmacogenomics in epilepsy. Neuroscience Letters. 2018;667:27\u201339. Epub 2017\/01\/14.","DOI":"10.1016\/j.neulet.2017.01.014"},{"key":"ref85","doi-asserted-by":"crossref","unstructured":"Cavalleri GL, McCormack M, Alhusaini S, Chaila E, Delanty N. Pharmacogenomics and epilepsy: the road ahead. Pharmacogenomics. 2011;12(10):1429\u20131447. Epub 2011\/10\/20.","DOI":"10.2217\/pgs.11.85"},{"key":"ref86","doi-asserted-by":"crossref","unstructured":"Clancy CE, Kass RS. Pharmacogenomics in the treatment of epilepsy. Pharmacogenomics. 2003;4(6):747\u2013751. Epub 2003\/11\/05.","DOI":"10.1517\/phgs.4.6.747.22822"},{"key":"ref87","doi-asserted-by":"crossref","unstructured":"Loscher W. Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs. 2002;16(10):669\u2013694. Epub 2002\/09\/25.","DOI":"10.2165\/00023210-200216100-00003"},{"key":"ref88","doi-asserted-by":"crossref","unstructured":"Chong KW, Chan DW, Cheung YB, Ching LK, Hie SL, Thomas T et al. Association of carbamazepine-induced severe cutaneous drug reactions and HLA-B*1502 allele status, and dose and treatment duration in paediatric neurology patients in Singapore. Archives of Disease in Childhood. 2014;99(6):581\u2013584. Epub 2013\/11\/15.","DOI":"10.1136\/archdischild-2013-304767"},{"key":"ref89","doi-asserted-by":"crossref","unstructured":"Cheung YK, Cheng SH, Chan EJ, Lo SV, Ng MH, Kwan P. HLA-B alleles associated with severe cutaneous reactions to antiepileptic drugs in Han Chinese. Epilepsia. 2013;54(7):1307\u20131314. Epub 2013\/05\/23.","DOI":"10.1111\/epi.12217"},{"key":"ref90","doi-asserted-by":"crossref","unstructured":"Hung SI, Chung WH, Liu ZS, Chen CH, Hsih MS, Hui RC et al. Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese. Pharmacogenomics. 2010;11(3):349\u2013356. Epub 2010\/03\/20.","DOI":"10.2217\/pgs.09.162"},{"key":"ref91","doi-asserted-by":"crossref","unstructured":"Janicki PK, Bezinover D, Postula M, Thompson RS, Acharya J, Acharya V et al. Increased Occurrence of Valproic Acid-Induced Hyperammonemia in Carriers of T1405N Polymorphism in Carbamoyl Phosphate Synthetase 1 Gene. ISRN Neurology. 2013;2013:261497. Epub 2013\/09\/03.","DOI":"10.1155\/2013\/261497"},{"key":"ref92","doi-asserted-by":"crossref","unstructured":"Li H, Wang X, Zhou Y, Ni G, Su Q, Chen Z et al. Association of LEPR and ANKK1 Gene Polymorphisms with Weight Gain in Epilepsy Patients Receiving Valproic Acid. The International Journal of Neuropsychopharmacology. 2015;18(7):pyv021. Epub 2015\/03\/06.","DOI":"10.1093\/ijnp\/pyv021"},{"key":"ref93","doi-asserted-by":"crossref","unstructured":"Budi T, Toth K, Nagy A, Szever Z, Kiss A, Temesvari M et al. Clinical significance of CYP2C9-status guided valproic acid therapy in children. Epilepsia. 2015;56(6):849\u2013855. Epub 2015\/05\/15.","DOI":"10.1111\/epi.13011"}],"container-title":["Psychopharmacology Bulletin"],"original-title":[],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:29:52Z","timestamp":1791314992000},"score":1,"resource":{"primary":{"URL":"https:\/\/medworksmedia.com\/pb-article\/myotoxicity-induced-by-antiepileptic-drugs-could-be-a-rare-but-serious-adverse-event\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":94,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,8,12]]}},"URL":"https:\/\/doi.org\/10.64719\/pb.4421","relation":{},"ISSN":["2472-2448"],"issn-type":[{"value":"2472-2448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,12]]}}}